Nivolumab (NIVO) plus relatlimab (RELA) with platinum-doublet chemotherapy (PDCT) vs pembrolizumab plus PDCT in patients (pts) with nonsquamous (NSQ), metastatic non-small cell lung cancer (NSCLC) and tumor PD-L1 expression ≥ 1%: RELATIVITY-1093 study rationale

relatlimab (BMS-986016) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Keytruda (pembrolizumab) - Merck (MSD)

Nivolumab (NIVO) plus relatlimab (RELA) with platinum-doublet chemotherapy (PDCT) vs pembrolizumab plus PDCT in patients (pts) with nonsquamous (NSQ), metastatic non-small cell lung cancer (NSCLC) and tumor PD-L1 expression ≥ 1%: RELATIVITY-1093 study rationale (ESMO-IO 2026) - Oct 25, 2026 - Abstract #307TiP; Pres time: Dec 14, 2026; 05:30 PM - 06:30 PM; Location: Churchill Room; No abstract available
Clinical • IO biomarker • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1 • RELA

https://cslide.ctimeetingtech.com/immuno2026/attendee/confcal/print/presentation/372

Michael Sc henker; Tudor-Eliade Ciuleanu; Jung Seop Eom; Hidetoshi Hayashi; Martin Reck; Mehmet Altan; Edward B. Garon; Nicolas Girard; Kenneth J. O'Byrne; Bohang Chen; Ko mal Sharma; Jay Marshall; Palanikumar Ravindran; Alexander Chung; Juan Carlos Vazquez Limon

Oct 25, 2026